Paper Details

  1. Home
  2. Paper Details

[Granulocyte-macrophage colony-stimulating factor. Treatment of patients with highly malignant lymphomas and acute lymphoblastic leukemias after autologous bone marrow transplantation].

Author: EllegaardJ, HoklandP, JensenI M, JessenP, NielsenB

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 10 patients who received a bone marrow transplant after high-dose radiation and chemotherapy found that treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF) led to faster recovery of white blood cells and a lower need for blood transfusions compared to a historical control group. GM-CSF treatment also significantly improved platelet levels. While GM-CSF treatment was associated with mild side effects in some patients, there was no significant difference in the incidence of severe complications, infections, or hospital stays between the groups. The study concludes that GM-CSF treatment is beneficial for patients undergoing bone marrow transplantation.
Paper Details　
Original Abstract of the Article :
We have evaluated the effect of intravenous infusions of granulocyte-macrophage colony-stimulating factor (GM-CSF) in ten patients undergoing autologous bone marrow transplantation after total body irradiation (11 Gy) and cyclophosphamide (120 mg/kg) conditioning for malignant lymphomas or acute lym...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1471304

データ提供：米国国立医学図書館（NLM）

GM-CSF: A Helping Hand for Bone Marrow Transplant Patients

The world of medicine is always looking for ways to help patients recover faster and better. This study dives deep into the use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients who have undergone autologous bone marrow transplantation. It's like giving a tired camel a refreshing oasis to help it regain its strength! The researchers used a specific treatment strategy involving total body irradiation and cyclophosphamide to condition the patients for the transplant. They then compared the recovery of patients who received GM-CSF with a historical control group who did not. The study revealed that GM-CSF may speed up the regeneration of neutrophils, a crucial component of the immune system, and decrease the need for blood transfusions. This means patients might bounce back quicker and experience less fatigue. However, while the study found some positive results, it also noted that GM-CSF didn't drastically reduce severe toxicity, infections, or hospital stays.

GM-CSF: A Potential Booster for Post-Transplant Recovery

The findings suggest that GM-CSF might be a valuable tool for aiding bone marrow transplant patients in their recovery. Imagine a camel traversing the desert, GM-CSF acts as a supportive oasis, making the journey smoother and less taxing.

GM-CSF: A Beacon of Hope for Faster Recovery

While more research is needed to confirm the long-term benefits of GM-CSF, the potential for faster recovery and reduced transfusion requirements could be beneficial for patients. GM-CSF might become a cornerstone in post-transplant care, helping patients navigate the challenging path to recovery.

Dr.Camel's Conclusion

GM-CSF could be a helpful tool in the post-transplant recovery journey, but more research is needed to understand its full potential. Like a camel crossing the desert, the path to recovery can be long and demanding, but with the right support, it becomes more manageable.

Date :
  1. Date Completed 1993-01-27
  2. Date Revised 2007-11-15
Further Info :

Pubmed ID

1471304

DOI: Digital Object Identifier

1471304

SNS
PICO Info
in preparation
Languages

Danish

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.